Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024

Immuneering Corp

2024-Q1 EPS reported -$0.49

Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.
Phase 1 data for IMM-1-104 shows well-tolerated safety; target lesion regression in >50% of patients at 320mg.
First patient dosed in Phase 2a of IMM-1-104; initial data from multiple arms expected in 2024.
First patient dosed in Phase 1/2a of IMM-6-415 (RAF/RAS mutations); initial PK/PD/safety data expected 2024.
FDA Fast Track designation for IMM-1-104 in pancreatic cancer; cash $71.3M expected to fund operations into H2 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immuneering Corp reported the first quarter ended March 31, 2024 results: net income Net loss attributable to common stockholders was $14.3 million, or $0.49 per share, EPS $0.49 per share.

Period: the first quarter ended March 31, 2024
Net income: Net loss attributable to common stockholders was $14.3 million, or $0.49 per share
EPS: $0.49 per share
Result: reported results

Exact text from the filing

Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2024

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.